Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

57 results about "Dasatinib" patented technology

This medication is used to treat certain types of cancer (chronic myeloid leukemia-CML, acute lymphoblastic leukemia-ALL).

Drug delivery system for treating osteoporosis caused by cell aging as well as preparation method and application of drug delivery system

The invention relates to a drug delivery system for treating osteoporosis caused by cell aging as well as a preparation method and application of the drug delivery system. The drug delivery system comprises a bone targeting ligand modified drug carrier and an anti-bone cell aging drug entrapped in the drug carrier, the bone targeting ligand is selected from any one of alendronate sodium, bisphosphate and analogues thereof, tetracycline, tartrate-resistant acid phosphatase TRAP binding peptide, pregnancy region protein or e-selectin; the anti-osteocyte senescence medicine comprises any one or a combination of at least two of dasatinib, quercetin, metformin, L-ascorbic acid, aspirin or fisetin. According to the prepared drug delivery system, the bioavailability of the drug can be effectively improved, targeted release of the drug in bone tissue is achieved, senescent cell enrichment is reduced, and the bone microenvironment is improved, so that a new strategy is provided for treating osteoporosis caused by cell senescence.
Owner:THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA

Use of dasatinib for treating endometriosis

The invention discloses an application of dasatinib in preparation of a medicine for treating endometriosis. The dasatinib can be used for treating endometriosis. The new application of the dasatinib in treating the endometriosis has important clinical significance on accurate treatment of the endometriosis.
Owner:NANJING MATERNITY & CHILD HEALTH CARE HOSPITAL

Method for improving NK cell viability under high-density culture condition

The invention relates to a method for improving NK cell viability under a high-density culture condition. Specifically, dasatinib is added into an NK cell culture system, so that the NK cell viability can be remarkably improved, cell expansion is not affected, and the killing activity of cells after cryopreservation recovery is better. The method provided by the invention solves the ubiquitous problems that the NK cell viability activity is reduced in the high-density amplification process of cells, the tumor cell killing activity is reduced after cryopreservation recovery and the like under the condition that the process route is not changed, has the characteristics of simplicity in operation, low cost, no dependence on the process mode and the like, and is suitable for industrial production. The method has a wide application prospect in the field of NK product production.
Owner:NEUKIO BIOTHERAPEUTICS (SHANGHAI) CO LTD

Micro-flow field preparation method of dasatinib nanocrystal

The invention discloses a micro-flow field preparation method of dasatinib nanocrystals. The method comprises the following steps: dissolving dasatinib in an organic solvent to serve as a solvent phase A; dissolving a surfactant in deionized water to serve as an anti-solvent phase B, simultaneously pumping the solvent phase A and the anti-solvent phase B into a micro-flow field device for full reaction, collecting dasatinib crystal dispersion liquid at an outlet, centrifuging to remove supernate, taking bottom precipitate, and performing vacuum drying to obtain the solid nanocrystal. According to the present invention, the micro-flow field device is adopted, the mixing process of the solvent and the anti-solvent is enhanced, the surfactant is adopted as the dispersant, the transport efficiency and the supersaturation degree of the drug molecules are regulated and controlled, the efficient preparation of the dasatinib nanocrystal is achieved, the operation is simple, the reaction speed is fast, and the safety is high.
Owner:NANJING TECH UNIV

Amorphous solid dispersions of dasatinib and uses thereof

Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection.
Owner:HANDA THERAPEUTICS LLC

Prevention or mitigation of adverse reactions associated with recombinant viral vectors

The present invention relates to the prevention or mitigation of adverse reactions associated with gene therapy, such as the formation of anti-drug antibodies. In particular, the present invention relates to the use of tyrosine kinase inhibitors, such as dasatinib, to prevent or ameliorate such side effects.
Owner:F HOFFMANN LA ROCHE & CO AG

Dasatinib drug sensitivity gene marker combination and drug sensitivity prediction system

The invention discloses a dasatinib drug sensitivity gene marker combination and a drug sensitivity prediction system. A signal interaction network is constructed and key regulatory factors are identified by comprehensively analyzing a gene expression profile, a gene marker combination remarkably related to the drug sensitivity of the dasatinib is obtained, and a prediction model can be trained through the gene markers and used for accurately predicting the drug sensitivity of the dasatinib, so that a reliable basis is provided for personalized treatment, and the drug sensitivity of the dasatinib is accurately predicted. And reference is provided for clinical treatment decisions.
Owner:SHANGHAI CINOPATH MEDICAL TESTING CO LTD

Methods for the treatment of glioblastoma multiforme

Methods for the treatment of cancer, including glioblastoma multiforme (GBM) and recurrent glioblastoma multiforme (RGBM). The method includes administering to a patient a plurality of extraneous antineoplastons and a plurality of targeted agents. The plurality of extraneous antineoplastons may include two or more antineoplastons selected from phenylacetylglutaminate sodium (PG), phenylacetylisoglutaminate sodium (iso-PG), and phenylacetate (PN). The plurality of targeted agents may include two or more agents selected from bevacizumab, pazopanib, sorafenib, dasatinib, and everolimus.
Owner:BURZYNSKI STANISLAW R

Polymer prodrug and preparation method and application of TPP-DOX-loaded nano-micelle of polymer prodrug

According to the invention, a polymer prodrug is designed and prepared, and a dasatinib (DAS) and triphenylphosphine-adriamycin (TPP-DOX, TD) co-loaded nano-micelle is constructed; the preparation method has the advantages that 1) the optimal preparation process of the polymer micelle is determined by a single factor investigation method, namely the optimal nano-micelle is prepared by using a dialysis method and taking DMF (Dimethyl Formamide) as a solvent according to the mass ratio of a prodrug material to a carried drug being 15: 1, and the preparation method is simple and clear and is easy to industrialize; 2) the particle size is small and uniform, so that the nanoparticles can be enriched at a tumor part through an EPR effect; 3) the amphiphilic micromolecule prodrug improves the water solubility of DAS, improves the drug stability, has high drug loading capacity, and avoids adverse reactions possibly caused by carriers and auxiliary materials; and 4) the polymer nano-micelle co-loaded with the DAS and the TPP-DOX has good MMP-2 sensitive responsiveness, enhances the drug targeting delivery capability, has good blood compatibility and safety, improves the drug curative effect, reduces the toxic and side effects, and has a good tumor MDR reversing effect.
Owner:HENAN UNIVERSITY

Amorphous solid dispersions of dasatinib and uses thereof

Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection.
Owner:HANDA THERAPEUTICS LLC

Nano-drug based on chondroitin sulfate as well as preparation method and application of nano-drug

The invention belongs to the field of biological medicine, and particularly relates to a nano-drug based on chondroitin sulfate as well as a preparation method and application of the nano-drug. Chondroitin sulfate (CS) and dasatinib (DAS) are connected through a GFLG connexon responded by cathepsin B (CTSB) to prepare the prodrug CS-GFLG-DAS (CGD), the prodrug CS-GFLG-DAS (CGD) is used for reversing the phenotype of cancer-related fibroblasts and reducing the biosynthesis of extracellular matrixes, fibrotic tumors are efficiently treated, and a new perspective is provided for optimizing the application of immunotherapy in fibrotic tumors.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Darcotinib pharmaceutical composition and preparation method thereof

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a dalcotinib pharmaceutical composition and a preparation method thereof.The dalcotinib pharmaceutical composition is prepared from, by weight, 10-30 parts of dalcotinib, 25-60 parts of lactose, 25-60 parts of microcrystalline cellulose, 1-15 parts of carboxymethyl starch sodium and 0.5-5 parts of magnesium stearate; the average particle size D50 of the lactose is greater than or equal to 120 microns. The dalcotinib composition disclosed by the invention is high in dissolution rate, quick in disintegration, good in fluidity, capable of avoiding sticking, good in dissolution rate stability and simple in preparation process.
Owner:成都硕德药业有限公司

Dasatinib vanillic acid crystal form and preparation method thereof

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a dasatinib vanillic acid crystal form and a preparation method thereof, and in the dasatinib vanillic acid crystal form provided by the invention, the molar ratio of dasatinib to vanillic acid to water is 1: 1: 1. The dasatinib vanillic acid crystal form provided by the invention has relatively good stability and relatively high dissolution rate, and is of great significance for improving the bioavailability of a dasatinib medicine and preparing a preparation.
Owner:LUNAN PHARMA GROUP CORPORATION

Application of dasatinib in preparation of medicine for promoting retina ganglion cell axon regeneration and dendritic repair

The invention belongs to the technical field of biological medicines, and discloses application of dasatinib in preparation of a medicine for promoting retina ganglion cell axon regeneration and dendritic repair. The research of the invention finds that dasatinib has the effect of promoting RGC axon regeneration and dendritic repair after optic nerve injury. When dasatinib is adopted for treatment, repair and regeneration of retinal ganglion cell axons and dendrites after optic nerve injury can be promoted, and the purpose of treating traumatic optic nerve injury is achieved.
Owner:SHANTOU UNIV·CHINESE UNIV OF HONG KONG JOINT SHANTOU INT OPHTHALMOLOGY CENT

NO donor type dasatinib derivative as well as preparation method and application thereof

The invention provides an NO donor type dasatinib derivative as well as a preparation method and application thereof. The derivative is one of a compound 1a-1f and a compound 2a-2f; the derivative has multiple effects of removing senescence cells, reducing intraocular pressure and protecting optic nerves, and is a novel potential treatment medicine for treating glaucoma and senescence-related retinopathy.
Owner:ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV +1

Application of pharmaceutical composition of dasatinib and quercetin in preparation of medicine for improving outcome of elderly adverse pregnancy

The invention relates to an application of a dasatinib and quercetin pharmaceutical composition in preparation of a medicine for improving the outcome of elderly adverse pregnancy, belongs to the technical field of biological medicines, and particularly discloses an application of the dasatinib and quercetin pharmaceutical composition. The technical problem of placenta dysfunction caused by elderly pregnancy is solved. The dasatinib and the quercetin form the pharmaceutical composition, so that the autophagy activity of trophoblasts is promoted, DNA (deoxyribonucleic acid) damaged cells are eliminated, the adverse pregnancy outcome caused by the elderly is remarkably improved, the embryo absorption rate is reduced by about 10%, and the weight of a fetus is increased by about 20mg. The invention provides a new targeted intervention strategy for the outcome of elderly adverse pregnancy.
Owner:CHONGQING MATERNAL & CHILD HEALTH HOSPITAL (CHONGQING OBSTETRICS & GYNECOLOGY HOSPITAL CHONGQING INST OF GENETICS & REPRODUCTION)

Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses

Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection. The compositions may be administered intact, or may be crushed prior to administration.
Owner:HANDA THERAPEUTICS LLC

Combination Therapy for Brain Cancer

PendingUS20260151423A1Solution deliveryPharmaceutical non-active ingredientsDuvelisibPanobinostat
Combination therapies for use in the treatment of brain tumours, particularly glioma and embryonal brain tumours. Disclosed herein are pharmaceutical compositions comprising a complex of Panobinostat and a cyclodextrin, a second pharmaceutical agent, and a pharmaceutically acceptable excipient, diluent or carrier, in which the second pharmaceutical agent is Niclosamide, Dasatinib or Duvelisib. Associated methods of treatment and use are further disclosed.
Owner:BIODEXA LTD

Treatment of canine cancers

Described herein are methods useful for the treatment of cancers in a canine subject with a pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. Also described herein are methods for identification of subjects with cancers that will benefit from administration of the pharmaceutical compositions comprising HIDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. In certain aspects, the methods described herein further comprise administering a therapeutically effective amount of at least one additional anti-cancer agent.
Owner:ONEHEALTHCOMPANY INC

Cryopreservation of NK cell products for spot immunotherapy

Provided herein are methods for inactivating effector cells (e.g., NK cells, including cells as spot type cells for adoptive cell therapy). The inactivated cells can be cryopreserved after inactivation. The inactivated cells may be expanded and / or activated prior to inactivation, and may or may not include a transgene, which may optionally encode a chimeric antigen receptor and / or a T cell receptor. In certain embodiments, disclosed are methods for inactivating NK cells comprising treating with an inactivating agent, which is a kinase inhibitor, such as an mTOR inhibitor, and / or a tyrosine kinase inhibitor, such as rapamycin and / or dasatinib. Also provided herein are inactivated and cryopreserved NK cells, and methods of making and / or using the same for treating a subject in need thereof (e.g., treating a subject having cancer).
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

A method for synthesizing a dasatinib intermediate

ActiveCN118994050BOrganic chemistryPivalic acidMethylaniline
The application discloses a kind of synthesis method of dasatinib intermediate in the field of organic synthesis, with 2-aminothiazole-4-carboxylic acid as raw material, first and tert-pivaloyl chloride in situ generates mixed anhydride, further and 2-chloro-6-methylaniline condensation reaction occurs after, the compound 2 obtained is not separated directly hydrolyzed to obtain high-purity 2-amino-N-(2-chloro-6-methylphenyl) thiazole-5-formamide.Due to the mixed anhydride formed by tert-pivaloyl chloride has greater steric hindrance, and the further reaction of corresponding amine is conducive to the regioselectivity, and by-product tert-pivalic acid can be easily removed by post-treatment, so as to solve the disadvantages existing in the prior art, the unit operation involved in the whole preparation process is simpler, and the product purity and yield are higher, with good application prospect.
Owner:GAOYOU CITY ORGANIC CHEM FACOTRY

Methods for the treatment of glioblastoma multiforme

Methods for the treatment of cancer, including glioblastoma multiforme (GBM) and recurrent glioblastoma multiforme (RGBM). The method includes administering to a patient a plurality of extraneous antineoplastons and a plurality of targeted agents. The plurality of extraneous antineoplastons may include two or more antineoplastons selected from phenylacetylglutaminate sodium (PG), phenylacetylisoglutaminate sodium (iso-PG), and phenylacetate (PN). The plurality of targeted agents may include two or more agents selected from bevacizumab, pazopanib, sorafenib, dasatinib, and everolimus.
Owner:BURZYNSKI STANISLAW R

Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer

The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a Src-family kinase inhibitor and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
Owner:MIRATI THERAPEUTICS INC

Cryopreservation of NK cell products for off-the-shelf immunotherapy

Provided herein are methods for deactivation of effector cells, such as NK cells, including cells for adoptive cell therapy that are off-the-shelf cells. The deactivated cells may be cryopreserved following deactivation. The deactivated and cell may be expanded and / or activated prior to deactivation, and may or may not comprise a transgene, which may optionally encode a chimeric antigen receptor and / or T cell receptor. In certain embodiments, disclosed are methods for deactivation of NK cells comprising treatment with a kinase inhibitor, for example an mTOR inhibitor and / or a tyrosine kinase inhibitor, for example rapamycin and / or Dasatinib. Also provided herein are deactivated and cryopreserved NK cells, and methods of preparing and / or using the same for treatment of a subject in need thereof, for example treatment of a subject with cancer.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Amorphous solid dispersions of dasatinib and uses thereof

Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection.
Owner:HANDA THERAPEUTICS LLC

Synthesis method of dasatinib intermediate

ActiveCN118994050Ahigh purityEasy to handle and removeOrganic chemistryMethylanilineOrganic synthesis
The invention discloses a synthetic method of a dasatinib intermediate, which belongs to the technical field of organic synthesis, and comprises the following steps: by taking 2-aminothiazole-4-formic acid as a raw material, firstly generating mixed anhydride with pivaloyl chloride in situ, then further performing condensation reaction with 2-chloro-6-methylaniline, and finally obtaining the dasatinib intermediate. And the obtained compound 2 is not separated and is directly hydrolyzed to obtain the high-purity 2-amino-N-(2-chloro-6-methylphenyl) thiazole-5-formamide. The mixed anhydride formed by pivaloyl chloride has large steric hindrance, further reaction with corresponding amine is beneficial to regioselectivity, and the byproduct pivaloyl acid can be easily removed through post-treatment, so that the defects in the prior art are overcome, the unit operation involved in the whole preparation process is simpler, and the cost is lower. And the product has high purity and yield, and has a good application prospect.
Owner:GAOYOU CITY ORGANIC CHEM FACOTRY

Use of m6a methylation level in lncrna-wee2-as1 as a glioma marker

The present application relates to the m 6 Application of methylation level of A as glioma marker, the present application confirms the m 6 The methylation modification level is related to the prognosis condition of brain glioma, and the increase of methylation abundance and expression level means worse prognosis. In addition, the present application researches and confirms that the expression of lncRNA-WEE2-AS1 is related to the formation of drug resistance of anti-tumor drugs, and inhibiting the expression of the lncRNA helps to improve the resistance of dasatinib, and provides a feasible treatment scheme for the clinical targeted treatment of drug-resistant patients.
Owner:SHANDONG UNIV QILU HOSPITAL

Method for reprogramming type 1 alveolar cells into type 2 alveolar cells using rhosin, dasatinib, or ML141, and composition for inhibiting lung cancer metastasis containing ML141 or dasatinib

[Method for reprogramming type 1 alveolar cells into type 2 alveolar cells using Rhosin] The present invention relates to a composition for inducing the reprogramming of type 1 alveolar cells into type 2 alveolar cells, the composition containing Rhosin as an active ingredient. According to the present invention, it is expected to be possible not only to reprogram AT1 cells into AT2 cells using Rhosin and thereby efficiently obtain AT2 cells which were previously difficult to obtain in sufficient numbers, but also to reprogram AT1 cells into AT2 cells in organoids while culturing the organoids themselves rather than culturing single cells, and thereby obtain cells having physiological activity more similar to that of actual tissue. [Method for reprogramming type 1 alveolar cells into type 2 alveolar cells using Dasatinib] The present invention relates to a composition for inducing the reprogramming of type 1 alveolar cells into type 2 alveolar cells, the composition containing Dasatinib as an active ingredient. According to the present invention, it is expected to be possible not only to reprogram AT1 cells into AT2 cells using Dasatinib and thereby efficiently obtain AT2 cells which were previously difficult to obtain in sufficient numbers, but also to reprogram AT1 cells into AT2 cells in organoids while culturing the organoids themselves rather than culturing single cells, and thereby obtain cells having physiological activity more similar to that of actual tissue. [Method for reprogramming type 1 alveolar cells into type 2 alveolar cells using ML141] The present invention relates to a composition for inducing the reprogramming of type 1 alveolar cells into type 2 alveolar cells, the composition containing ML141 as an active ingredient. According to the present invention, it is expected to be possible not only to reprogram AT1 cells into AT2 cells using ML141 and thereby efficiently obtain AT2 cells which were previously difficult to obtain in sufficient numbers, but also to reprogram AT1 cells into AT2 cells in organoids while culturing the organoids themselves rather than culturing single cells, and thereby obtain cells having physiological activity more similar to that of actual tissue. [ML141-containing composition for inhibiting lung cancer metastasis] The present invention relates to a composition for inhibiting lung cancer metastasis, the composition containing ML141 as an active ingredient. [Dasatinib-containing composition for inhibiting lung cancer metastasis] The present invention relates to a composition for inhibiting lung cancer metastasis, the composition containing Dasatinib as an active ingredient.
Owner:THE CATHOLIC UNIV OF KOREA IND ACADEMIC COOP FOUND

A method for regulating CAR-T cells and its application

The present invention discloses a method for regulating CAR-T cells and its application. The present invention regulates CAR-T cells through tyrosine kinase inhibitors, thereby alleviating and treating immune-related toxicities that may occur after CAR-T cells are used for treatment. The regulation method of the present invention can regulate the expression of various cytokines related to CAR-T cell immunotoxicity, perform early intervention on related toxicities, reduce the incidence and mortality of severe toxicities, and thus improve the safety of CAR-T cells. Dasatinib in the regulation method used in the present invention is an anti-tumor drug that has been approved for clinical treatment and can be applied in the treatment of various cancers, enabling the reuse of old drugs and having great economic value.
Owner:GUANGZHOU ANJIE BIOMEDICAL TECH CO LTD